Key result
HCM mortality in Brazil climbs from 2010 to 2020, with regional increases reaching ~70%.
Why the study?
Healthcare system limitations, socioracial factors, and underdiagnosis hinder accurate assessments of hypertrophic cardiomyopathy mortality in Brazil.
Population
Individuals with HCM-related deaths in Brazil from 2010 to 2020
Comparison
Socioracial factors and healthcare disparities over time
Design
Ecological time-series study using secondary mortality data
Authors
Loading...
Rising HCM mortality in Brazil signals monitoring needs; leaves open regional drivers and equity-focused prevention trials.
Observational
Yes
HCM-related mortality in Brazil increased significantly between 2010 and 2020, particularly among white and brown individuals aged 40 and older, highlighting regional healthcare disparities.
Santos et al. (2024) conducted an observational in Hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy-related mortality in Brazil increased from 2010 to 2020, with the incidence of deaths rising by 18.3% and 69.8% in the northeastern and southeastern regions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: